Tenvie Therapeutics, a San Francisco, CA-based biotechnology company committed to engineering small molecules for the treatment of neurological diseases, raised $200M in funding.
The round was led by ARCH Venture Partners, F-Prime Capital, Mubadala Capital, with participation from other investors.
The company intends to use the funds to accelerate its growth and development efforts.
Tenvie is a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases. Its foundation is purpose-built with a diverse portfolio of small molecules and a proven team of CNS drug developers to rapidly deliver multiple clinical assets. The company is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function.
The company’s most advanced programs target NLRP3 and SARM1, with additional programs in preclinical development
Its Board of Directors includes:
- Tony Estrada, Ph.D., President, Chief Scientific Officer and Board Director
- Brian Cuneo, J.D., Chief Business and Legal Officer
- Tanya Fischer, M.D., Ph.D., Chief Medical Officer
- Paul L. Berns, Executive Chair of Tenvie’s Board, Managing Director, ARCH Venture Partners
- Kristina Burow, Tenvie Board Director, Managing Director, ARCH Venture Partners
- Alaa Halawa, Tenvie Board Director, Head of Healthcare and Executive Director, Mubadala Capital
- Joe Lewcock, Ph.D., Tenvie Board Director, Chief Scientific Officer, Denali Therapeutics
- Stacie Weninger, Ph.D., Tenvie Board Director, President, FBRI, Venture Partner, F-Prime Capital
FinSMEs
08/01/2025